{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:22:50Z","timestamp":1778617370986,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020638","name":"Kementerian Riset dan Teknologi \/Badan Riset dan Inovasi Nasional","doi-asserted-by":"publisher","award":["586\/UN3.14\/ PT \/2020"],"award-info":[{"award-number":["586\/UN3.14\/ PT \/2020"]}],"id":[{"id":"10.13039\/501100020638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020638","name":"Kementerian Riset dan Teknologi \/Badan Riset dan Inovasi Nasional","doi-asserted-by":"publisher","award":["295\/UN3.15\/ PT \/2021"],"award-info":[{"award-number":["295\/UN3.15\/ PT \/2021"]}],"id":[{"id":"10.13039\/501100020638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020473","name":"Badan Riset dan Inovasi Nasional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tube.2025.102675","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:28:42Z","timestamp":1753313322000},"page":"102675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Population pharmacokinetics of levofloxacin in drug-susceptible and drug-resistant tuberculosis patients: Optimal dose suggestion based on renal function"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-1123","authenticated-orcid":false,"given":"Yong-Soon","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rannissa Puspita","family":"Jayanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousang","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsoo","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heayon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soedarsono","family":"Soedarsono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon-Jeong","family":"Seong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2025.102675_bib1","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"10.1016\/j.tube.2025.102675_bib2","series-title":"Global tuberculosis report","year":"2023"},{"key":"10.1016\/j.tube.2025.102675_bib3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2025.102675_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jcph.1534","article-title":"Effects of the fluoroquinolones moxifloxacin and levofloxacin on the QT subintervals: sex differences in ventricular repolarization","volume":"60","author":"Taubel","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.tube.2025.102675_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13665-013-0063-z","article-title":"Management of drug-resistant tuberculosis","volume":"2","author":"Scardigli","year":"2013","journal-title":"Current Respiratory Care Reports"},{"key":"10.1016\/j.tube.2025.102675_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tube.2025.102675_bib7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and bayesian dose adjustment to advance TDM of Anti-TB drugs","volume":"60","author":"Sturkenboom","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tube.2025.102675_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00343-17","article-title":"Pharmacokinetics of levofloxacin in Multidrug- and extensively drug-resistant tuberculosis patients","volume":"61","author":"Van't Boveneind-Vrubleuskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/ciu1146","article-title":"Acquired drug resistance: we can do more than we think","volume":"60","author":"Alffenaar","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03463-2020","article-title":"Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China","volume":"57","author":"Davies Forsman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2025.102675_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02107-2018","article-title":"Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients","volume":"53","author":"Ghimire","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2025.102675_bib12","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.tube.2025.102675_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050990","article-title":"Semi-automated therapeutic drug monitoring as a pillar toward personalized medicine for tuberculosis management","volume":"14","author":"Jayanti","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tube.2025.102675_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262318","article-title":"Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia","volume":"17","author":"Wakjira","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2025.102675_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.21037\/qims-21-290","article-title":"Differentiating between drug-sensitive and drug-resistant tuberculosis with machine learning for clinical and radiological features","volume":"12","author":"Yang","year":"2022","journal-title":"Quant Imag Med Surg"},{"key":"10.1016\/j.tube.2025.102675_bib17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/QAI.0000000000001705","article-title":"Risk of nephrotoxicity in patients with drug-resistant tuberculosis treated with kanamycin\/capreomycin with or without concomitant use of tenofovir-containing antiretroviral therapy","volume":"78","author":"Perumal","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.tube.2025.102675_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3349\/ymj.2020.61.12.1034","article-title":"Characteristics and treatment outcomes of isoniazid mono-resistant tuberculosis: a retrospective study","volume":"61","author":"Kwak","year":"2020","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.tube.2025.102675_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107230","article-title":"Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: insights from the TB-TRUST and TB-TRUST-plus trials","volume":"148","author":"Song","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/AAC.01036-07","article-title":"Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis","volume":"52","author":"Peloquin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1473-3099(24)00223-8","article-title":"Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial","volume":"24","author":"Cevik","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib22","first-page":"131","article-title":"Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis","volume":"167","author":"Papastavros","year":"2002","journal-title":"CMAJ (Can Med Assoc J)"},{"key":"10.1016\/j.tube.2025.102675_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2023.102325","article-title":"Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis","volume":"139","author":"Soedarsono","year":"2023","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2025.102675_bib24","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcph.1931","article-title":"Personalized precision medicine of, isoniazid population pharmacokinetics and dose recommendation for Korean patients with tuberculosis based on target attainment analysis","volume":"61","author":"Cho","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.tube.2025.102675_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2022.01.003","article-title":"Development of population pharmacokinetics model of isoniazid in Indonesian tuberculosis patients","author":"Soedarsono","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"102","author":"Kim","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.tube.2025.102675_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijid.2022.07.029","article-title":"Pharmacokinetics and safety of WHO-recommended dosage and higher dosage of levofloxacin for tuberculosis treatment in children: a pilot study","volume":"122","author":"Jantarabenjakul","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib28","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkw164","article-title":"Pharmacokinetic\/Pharmacodynamic-Based optimization of levofloxacin administration in the treatment of MDR-TB","volume":"71","author":"Ghimire","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib29","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1093\/cid\/ciy611","article-title":"Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2025.102675_bib30","first-page":"17","article-title":"An age-calibrated definition of chronic kidney disease: rationale and benefits","volume":"37","author":"Delanaye","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.tube.2025.102675_bib31","first-page":"19","article-title":"Chapter 1: definition and classification of CKD","volume":"3","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.tube.2025.102675_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01092-18","article-title":"Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients","volume":"62","author":"van den Elsen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00279-19","article-title":"Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic\/pharmacodynamic target attainment to guide dose selection","volume":"63","author":"Al-Shaer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib34","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/AAC.00341-15","article-title":"Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis","volume":"59","author":"Alsultan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib35","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1128\/AAC.42.5.1098","article-title":"Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection","volume":"42","author":"Preston","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib36","article-title":"Influence of renal function and age on the pharmacokinetics of levofloxacin in patients with bone and joint infections","volume":"9","author":"Eloy","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.tube.2025.102675_bib37","doi-asserted-by":"crossref","first-page":"8930","DOI":"10.1038\/s41598-022-12627-1","article-title":"Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients","volume":"12","author":"Setiawan","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2025.102675_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1179\/1973947815Y.0000000033","article-title":"Population pharmacokinetics of levofloxacin in Korean patients","volume":"28","author":"Kiem","year":"2016","journal-title":"J Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.24892","article-title":"Association of higher-dose fluoroquinolone therapy with serious adverse events in older adults with advanced chronic kidney disease","volume":"5","author":"Muanda","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tube.2025.102675_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/bdd.2294","article-title":"Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy","volume":"42","author":"Boonpeng","year":"2021","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.tube.2025.102675_bib41","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkq091","article-title":"Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data","volume":"65","author":"Angeby","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2025.102675_bib42","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.202407-1354OC","article-title":"Efficacy and safety of higher doses of levofloxacin for multidrug-resistant tuberculosis: a randomized, placebo-controlled phase II clinical trial","volume":"211","author":"Phillips","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2025.102675_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0091270004264643","article-title":"Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings","volume":"44","author":"Noel","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.tube.2025.102675_bib44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/phar.1761","article-title":"Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk?","volume":"36","author":"Bidell","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tube.2025.102675_bib45","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics","volume":"164","author":"Yonezawa","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.tube.2025.102675_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp060082j","article-title":"Identification of influx transporter for the quinolone antibacterial agent levofloxacin","volume":"4","author":"Maeda","year":"2007","journal-title":"Mol Pharm"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979225000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979225000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:55:24Z","timestamp":1778615724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979225000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"alternative-id":["S1472979225000708"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2025.102675","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of levofloxacin in drug-susceptible and drug-resistant tuberculosis patients: Optimal dose suggestion based on renal function","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2025.102675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102675"}}